EGFR and non-small cell lung carcinoma: In another retrospective clinical study (GioTag study), advanced EGFR-mutated NSCLC patients receiving first-line afatinib followed by osimertinib had a median OS of 37.6 months and 44.8 months in Asian patients (37, 38).